Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Sohail Tavazoie

Co-founder & Chair of Scientific Advisory Board

Dr. Sohail Tavazoie is the Leon Hess Professor, Howard Hughes Medical Institute Faculty Scholar and Head of the Meyer Laboratory of Systems Cancer Biology at The Rockefeller University. He is the director of the Black Center for Metastasis Research at Rockefeller University and a medical oncologist at Memorial Sloan Kettering Cancer.

He received his undergraduate degree from the University of California at Berkeley and his M.D. and Ph.D. degrees from Harvard Medical School. Following internship and residency training at Brigham and Women’s Hospital and postdoctoral training at Harvard, he conducted oncology fellowship training at Memorial Sloan Kettering Cancer Center. Sohail has been the recipient of the NIH Innovator Award, the Pershing Square Sohn Cancer Prize, and the DOD Era of Hope Award. He is an elected member of the American Society of Clinical Investigation and a member of the National Academy of Medicine’s emerging leaders’ forum.